I believe the approach has potential to set a new standard of care in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective. Read More
TTX-330 Orthopedics is a therapeutic and bioresorbable polymer combination that helps reduce fibrosis following joint surgeries.
TTX 334 is a novel therapeutic candidate being studied for the treatment of endometriosis.
TTX 334 Oncology development of a novel therapeutic based on the discovery of a novel target found in a range of solid tumors, particularly resistant cancers.
Chairman, Previous VP International Marketing, Abbott
SVP, Corporate Business Development, Mission Pharmacal Company
Managing Director, Yorkville Advisors
Senior Director, GCIC, Cleveland Clinic
CEO 4P Therapeutics Previous VP of Altea, Durect, Kimberly Clark
VP, Associate General Counsel, IP, Emergent BioSolutions
Mexican Businessman and Entrepreneur
Previously CEO, Check-Cap, Ltd
Chief Financial Officer, Lineage Cell Therapeutics, Inc.
CEO
Chief Scientific Officer
Chief Medical Officer & Global Medical Lead
Chief Strategic Counsel
MD, Clinical Advisor
MD, MPH
MD, MSc, PhD
PhD, MD, FRCS
MS, PhD, FEAS, FCAHS
Supports Evitar’s™ Novel Approach for Preventing Acute Tissue Fibrosis (Surgical Adhesions) Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until now.
Read More
“Evitar™ offers a potential therapeutic option for preventing adhesion formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”... Read More
Evitar™ provides a totally new pre-emptive concept, that actively intervenes in the molecular pathway of adhesion formation."... Read More
Urmonderbaan 22 (Gate 2) 6167 RD Geleen Netherlands
PO Box 18 6160 MD Geleen Netherlands
info@templerx.com
© 2019 Temple Therapeutics BV. All Rights Reserved
Website Design & Developed by 2Web Design
